CFTR and cystic fibrosis: Considering the state of recurring chronic pulmonary infections of CF patients, and the consequent inflammation-associated tissue damage, which in many cases leads to lung failure (Esther et al., 2010), in this work we sought to determine whether the in vitro administration of PS-L to Mab-infected macrophages, whose CFTR has been pharmacologically inhibited or not, might be beneficial in term of enhanced antimicrobial capabilities and re-balanced inflammatory response.